Global Visceral Leishmaniasis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Visceral Leishmaniasis Market Size

• The global visceral leishmaniasis market size was valued at USD 37.40 million in 2025 and is expected to reach USD 74.52 million by 2033, at a CAGR of 9.00% during the forecast period
• The market growth is primarily driven by the rising prevalence of parasitic infections in tropical and subtropical regions, along with increasing focus on neglected tropical disease (NTD) control programs and improved diagnostic capabilities
• Furthermore, growing government and NGO-led initiatives for early detection, expanded access to antileishmanial therapies, and advancements in treatment protocols are strengthening disease management outcomes. These converging factors are accelerating the uptake of effective visceral leishmaniasis solutions, thereby significantly boosting the industry's growth

Visceral Leishmaniasis Market Analysis

• Visceral leishmaniasis, a life-threatening parasitic infection affecting internal organs, is gaining increasing global attention within infectious disease control frameworks due to persistent endemic transmission in tropical and subtropical regions and strengthened efforts toward neglected tropical disease elimination supported by international health agencies and public health programs
• The escalating demand for visceral leishmaniasis diagnosis and treatment is primarily fueled by rising incidence in endemic geographies, improved disease surveillance and reporting systems, and expanding access to effective antiparasitic therapies through government-funded treatment initiatives and global health partnerships
• North America dominated the visceral leishmaniasis market with the largest revenue share of 38.6% in 2025, characterized by strong research infrastructure, high healthcare spending, and advanced diagnostic capabilities, with the U.S. witnessing growing clinical awareness and imported case detection supported by specialized infectious disease centers and academic research institutions
• Asia-Pacific is expected to be the fastest growing region in the visceral leishmaniasis market during the forecast period due to high disease burden in countries such as India, increasing government elimination programs, and expanding rural healthcare access improving early diagnosis and treatment coverage
• The antiparasitic treatment segment dominated the visceral leishmaniasis market with the largest market share of 62.4% in 2025, driven by widespread use of first-line drugs such as amphotericin-based therapies, increasing adoption of standardized treatment guidelines, and strong reliance on effective parasite-targeting regimens in both hospital and public health settings

Report Scope and Visceral Leishmaniasis Market Segmentation      

Visceral Leishmaniasis Market Trends

“Enhanced Disease Detection Through Rapid Diagnostics and Treatment Innovation”

• A significant and accelerating trend in the global visceral leishmaniasis market is the increasing adoption of rapid diagnostic tools and molecular testing technologies that enable early and accurate detection of infection in endemic regions, thereby improving treatment outcomes and reducing disease-related mortality
• For instance, rK39 rapid diagnostic tests are widely used in India and East Africa to quickly identify visceral leishmaniasis cases at primary healthcare levels without requiring advanced laboratory infrastructure
• Integration of improved diagnostic platforms with treatment pathways is enabling faster initiation of antiparasitic therapy, with some programs using point-of-care testing combined with immediate drug administration to reduce disease progression risks
• Furthermore, advancements in drug delivery systems such as liposomal formulations of amphotericin B are improving treatment safety and reducing toxicity compared to conventional therapies, enhancing patient compliance and recovery rates
• This trend toward faster, more accurate diagnosis and improved therapeutic formulations is reshaping disease management strategies, with organizations such as WHO promoting elimination programs based on early detection and standardized treatment protocols
• The demand for improved diagnostic and therapeutic solutions is growing rapidly across endemic regions as healthcare systems prioritize early intervention to control transmission and reduce long-term disease burden
• Moreover, rising research into vaccine development and immunotherapy-based approaches is emerging as a long-term trend aimed at reducing dependency on chemotherapy-based treatments

Visceral Leishmaniasis Market Dynamics

Driver

“Rising Disease Burden and Global Elimination Initiatives Driving Treatment Demand”

• The increasing prevalence of visceral leishmaniasis in endemic regions, particularly in South Asia, East Africa, and parts of South America, is a major driver accelerating demand for effective diagnostic and treatment solutions
• For instance, national elimination programs in India and Bangladesh have significantly increased case detection and treatment coverage through government-supported public health initiatives
• Growing awareness of neglected tropical diseases and their socioeconomic impact is encouraging international organizations such as WHO and NGOs to expand funding for control and eradication programs
• Furthermore, improved healthcare infrastructure in rural and semi-urban regions is enabling better access to diagnostic tools and antiparasitic drugs, supporting early intervention strategies
• The rising availability of effective first-line therapies such as amphotericin B and miltefosine is further strengthening treatment adoption rates across endemic countries
• In addition, increasing collaboration between governments and global health agencies is enhancing surveillance systems and accelerating disease elimination efforts
• Moreover, rising investments in infectious disease research are supporting the development of improved diagnostics and next-generation therapeutic solutions
• Expanding public health screening programs in high-risk communities are also increasing early case identification, boosting overall treatment uptake

Restraint/Challenge

“Limited Healthcare Access and Drug Toxicity Concerns Hindering Market Expansion”

• Limited access to healthcare infrastructure in remote and rural endemic regions remains a major challenge, restricting timely diagnosis and effective treatment of visceral leishmaniasis cases
• For instance, in several low-income countries, patients often face delays in diagnosis due to lack of laboratory facilities and trained healthcare professionals, leading to advanced disease progression
• High toxicity and side effects associated with some antiparasitic drugs, such as amphotericin B and antimonial compounds, can reduce patient compliance and complicate treatment regimens
• Furthermore, irregular drug supply chains and dependence on donor-funded procurement programs create inconsistencies in treatment availability in vulnerable regions
• The high cost of safer and more advanced formulations, such as liposomal amphotericin B, limits widespread adoption in resource-constrained healthcare systems
• In addition, underreporting of cases and weak disease surveillance systems in some endemic areas hinder accurate epidemiological tracking and effective policy implementation
• Moreover, lack of awareness among rural populations often leads to delayed medical consultation, increasing disease severity and treatment complexity
• In addition, limited availability of skilled healthcare professionals trained in managing rare parasitic diseases further restricts effective disease control and treatment outcomes

Visceral Leishmaniasis Market Scope

The market is segmented on the basis of disease type, treatment, route of administration, end-users, and distribution channel.

• By Disease Type

On the basis of disease type, the market is segmented into cutaneous leishmaniasis, mucosal leishmaniasis, and visceral leishmaniasis. The visceral leishmaniasis segment dominated the market with the largest revenue share of 64.8% in 2025, driven by its high fatality rate if left untreated and its strong clinical priority in endemic regions. This form affects vital organs such as the spleen and liver, requiring urgent medical intervention and standardized treatment protocols. Public health programs and global elimination initiatives primarily focus on visceral cases due to their severe systemic impact. In addition, higher hospitalization rates and stronger diagnostic attention further reinforce its dominance. Government-funded treatment programs also prioritize visceral cases, increasing therapy uptake. The segment continues to benefit from improved surveillance systems and early detection initiatives in high-burden regions.

The cutaneous leishmaniasis segment is expected to witness the fastest growth rate of 9.6% from 2026 to 2033, driven by its widespread occurrence across tropical and subtropical regions and increasing awareness of skin-related parasitic infections. Rising outpatient diagnoses and expanding dermatology-based screening programs are contributing to higher detection rates. Improved accessibility of topical and oral treatments is supporting faster disease management in non-critical cases. In addition, growing cosmetic and quality-of-life concerns among patients are encouraging earlier treatment-seeking behavior. Increasing rural healthcare outreach is improving identification of mild cases that were previously underreported. Furthermore, enhanced surveillance programs in endemic regions are expanding case reporting, accelerating segment growth.

• By Treatment

On the basis of treatment, the market is segmented into antiparasitic, antifungal, and others. The antiparasitic segment dominated the market with the largest revenue share of 62.4% in 2025, driven by its status as the primary and most effective treatment approach for visceral leishmaniasis. Drugs such as amphotericin B and miltefosine remain the global standard of care across endemic regions. Strong clinical guidelines recommend antiparasitic therapy as first-line treatment, ensuring widespread adoption. Government procurement programs and international health funding further support accessibility in low-income countries. High treatment efficacy in reducing parasite load and mortality reinforces its dominance. In addition, continuous improvements in drug formulations are enhancing safety and patient compliance.

The “others” treatment segment is expected to witness the fastest CAGR of 8.8% from 2026 to 2033, driven by growing research into combination therapies and adjunct immunomodulatory treatments. Increasing focus on reducing drug toxicity and treatment duration is encouraging development of alternative therapeutic approaches. Clinical trials exploring novel compounds and repurposed drugs are expanding treatment options beyond conventional antiparasitics. Rising demand for safer and more tolerable therapies is also supporting innovation in this segment. In addition, integration of supportive therapies in severe cases is gaining traction in hospital settings. Expanding research funding for neglected tropical diseases is further accelerating pipeline development.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral, injectable, and others. The injectable segment dominated the market with the largest revenue share of 68.1% in 2025, driven by the high clinical effectiveness of intravenous and intramuscular therapies in treating severe visceral infections. Drugs such as liposomal amphotericin B are primarily administered via injection to ensure rapid systemic action. Hospital-based treatment protocols strongly favor injectable forms due to better bioavailability and faster parasite clearance. Severe disease cases require immediate therapeutic response, reinforcing injectable dominance. Government-supported treatment programs widely distribute injectable formulations in endemic regions. In addition, established clinical guidelines recommend injectable therapies as first-line treatment for advanced cases.

The oral segment is expected to witness the fastest CAGR of 10.2% from 2026 to 2033, driven by increasing preference for patient-friendly and non-invasive treatment options. Oral drugs such as miltefosine are gaining popularity due to ease of administration and reduced hospitalization needs. Expanding healthcare access in rural regions is supporting home-based treatment adoption. Improved formulation stability and effectiveness are increasing physician confidence in oral therapies. In addition, rising focus on reducing treatment costs and hospital burden is encouraging oral drug usage. Growing research into novel oral antiparasitic agents is further accelerating segment expansion.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the market with the largest revenue share of 71.5% in 2025, driven by the need for intensive care and supervised administration of injectable antiparasitic drugs. Severe visceral leishmaniasis cases require hospitalization for monitoring and complication management. Hospitals are the primary centers for diagnostic confirmation and treatment initiation. Availability of advanced diagnostic infrastructure supports their dominant role. Government-funded treatment programs are largely implemented through public hospitals in endemic regions. In addition, presence of skilled healthcare professionals ensures effective disease management in hospital settings.

The homecare segment is expected to witness the fastest CAGR of 11.4% from 2026 to 2033, driven by increasing adoption of oral therapies and decentralization of healthcare services. Patients with mild or recovering conditions are increasingly managed outside hospital settings. Rising healthcare costs are encouraging shift toward home-based treatment models. Improved patient monitoring technologies are enabling remote care support. Expanding rural healthcare outreach programs are also facilitating home treatment adoption. In addition, increasing awareness and caregiver training are supporting safe at-home disease management.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market with the largest revenue share of 76.3% in 2025, driven by the centralized distribution of critical antiparasitic drugs used in hospital-based treatment protocols. Most injectable therapies are dispensed directly through hospital systems to ensure controlled administration. Government procurement programs for visceral leishmaniasis drugs are primarily routed through hospital pharmacies. Strong regulatory oversight ensures proper drug usage in clinical environments. In addition, hospital pharmacies play a key role in managing supply chains for high-cost medications such as liposomal amphotericin B. Their integration with public health programs further strengthens dominance.

The online pharmacy segment is expected to witness the fastest CAGR of 12.1% from 2026 to 2033, driven by increasing digitization of healthcare services and improved access to medications in remote regions. Growing adoption of e-pharmacy platforms is enhancing drug availability in underserved areas. Patients prefer online channels due to convenience and home delivery options. Expansion of telemedicine services is further supporting digital prescription fulfillment. In addition, increasing smartphone penetration in developing regions is enabling wider adoption of online pharmacy services. Regulatory improvements supporting e-pharmacy operations are also accelerating segment growth.

Visceral Leishmaniasis Market Regional Analysis

• North America dominated the visceral leishmaniasis market with the largest revenue share of 38.6% in 2025, characterized by strong research infrastructure, high healthcare spending, and advanced diagnostic capabilities
• Healthcare systems in the region highly prioritize early diagnosis, advanced molecular testing, and effective treatment protocols, ensuring better disease management and improved patient outcomes for rare infectious diseases such as visceral leishmaniasis
• This regional dominance is further supported by high healthcare expenditure, strong research and development activities in neglected tropical diseases, and the presence of specialized infectious disease centers and academic institutions focusing on innovative diagnostics and therapeutics

U.S. Visceral Leishmaniasis Market Insight

The U.S. visceral leishmaniasis market captured the largest revenue share within North America in 2025, driven by advanced healthcare infrastructure, strong infectious disease surveillance systems, and high adoption of molecular diagnostic technologies. Increasing international travel and immigration from endemic regions contribute to the detection of imported cases, requiring specialized clinical management and hospital-based treatment. In addition, strong research funding for rare and neglected tropical diseases, along with the presence of leading academic medical centers and biotech companies, is supporting innovation in diagnostics and therapeutic development. The integration of advanced laboratory testing and rapid diagnostic tools further strengthens early detection and disease control efforts across the country.

Europe Visceral Leishmaniasis Market Insight

The Europe visceral leishmaniasis market is projected to grow at a substantial CAGR during the forecast period, driven by increasing awareness of tropical and travel-associated infectious diseases along with strengthened diagnostic surveillance systems. Rising cross-border movement and international travel are contributing to higher detection of imported cases, encouraging healthcare systems to improve early screening and reporting frameworks. In addition, growing investments in research for neglected tropical diseases and the expansion of hospital-based diagnostic capabilities are supporting improved disease management and therapeutic development across the region.

U.K. Visceral Leishmaniasis Market Insight

The U.K. visceral leishmaniasis market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by increasing awareness of imported infectious diseases and enhanced diagnostic capabilities within the national healthcare system. Rising international travel and immigration from endemic regions are contributing to sporadic case detection in hospitals and specialized clinics. Furthermore, strong public healthcare infrastructure, combined with advanced laboratory networks and infectious disease monitoring programs, is enabling timely diagnosis and effective patient management, thereby supporting market growth.

Germany Visceral Leishmaniasis Market Insight

The Germany visceral leishmaniasis market is expected to expand at a considerable CAGR during the forecast period, driven by increasing focus on rare disease diagnostics and strong healthcare infrastructure supporting infectious disease identification. Growing adoption of advanced molecular testing and laboratory-based diagnostic methods is improving early detection of imported cases. In addition, Germany’s robust research ecosystem and strong investments in tropical disease studies are contributing to advancements in diagnostic technologies and improved treatment strategies, further strengthening the market outlook.

Asia-Pacific Visceral Leishmaniasis Market Insight

The Asia-Pacific visceral leishmaniasis market is poised to grow at the fastest CAGR of 10.8% during the forecast period of 2026 to 2033, driven by high disease prevalence, expanding government elimination programs, and improving rural healthcare access. Countries such as India, Bangladesh, and Nepal are actively implementing large-scale public health interventions aimed at early detection and disease control. In addition, increasing international funding support, combined with rising healthcare infrastructure development, is significantly improving access to diagnostics and effective treatment options across endemic regions.

Japan Visceral Leishmaniasis Market Insight

The Japan visceral leishmaniasis market is gaining momentum due to rising awareness of imported infectious diseases and the presence of a highly advanced healthcare and diagnostic infrastructure. Although local transmission is rare, increased international travel has led to occasional case detection requiring specialized clinical attention. Integration of advanced laboratory diagnostics, along with strong hospital-based surveillance systems, is supporting accurate disease identification and effective treatment management within the country’s healthcare framework.

India Visceral Leishmaniasis Market Insight

The India visceral leishmaniasis market accounted for the largest market revenue share in Asia Pacific in 2025, driven by high endemic disease burden, strong government-led elimination programs, and extensive public health initiatives. Large-scale rural healthcare outreach and national kala-azar eradication efforts are significantly improving early diagnosis and treatment coverage across affected regions. In addition, expanding healthcare infrastructure, supported by international health organizations, is enhancing access to effective antiparasitic therapies and strengthening overall disease control and prevention strategies.

Visceral Leishmaniasis Market Share

The Visceral Leishmaniasis industry is primarily led by well-established companies, including:

• Sanofi (France)
• GSK plc (U.K.)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Sun Pharmaceutical Industries Ltd. (India)
• Cipla Limited (India)
• Lupin Limited (India)
• Glenmark Pharmaceuticals Ltd. (India)
• Zydus Lifesciences Ltd. (India)
• Hetero Drugs Limited (India)
• Abbott (U.S.)
• Dr. Reddy’s Laboratories Ltd. (India)
• Viatris Inc. (U.S.)
• Astellas Pharma Inc. (Japan)
• Eisai Co., Ltd. (Japan)
• Intra-Cellular Therapies, Inc. (U.S.)

What are the Recent Developments in Global Visceral Leishmaniasis Market?

• In November 2025, a clinical case study published in a global medical journal highlighted the re-emergence of diagnostic challenges in visceral leishmaniasis in non-endemic regions. The study described complex imported cases in elderly patients, emphasizing delayed diagnosis due to low clinical suspicion in developed healthcare systems. It stressed the importance of travel history awareness among clinicians for timely identification
• In October 2025, WHO and DNDi highlighted major progress in South Asia’s kala-azar elimination program, marking two decades of coordinated efforts across India, Bangladesh, and Nepal. The report emphasized significant reductions in visceral leishmaniasis incidence due to large-scale government interventions, improved vector control, and expanded access to rapid diagnostic testing
• In May 2025, the World Health Organization and African Union-supported member states announced strengthened cross-border collaboration to accelerate the elimination of visceral leishmaniasis in East Africa. The initiative focuses on harmonizing surveillance systems, improving early diagnosis, and ensuring consistent treatment protocols across endemic countries
• In May 2025, African Union–supported health ministries and WHO partners expanded a coordinated elimination initiative targeting visceral leishmaniasis across East Africa, strengthening cross-border surveillance and integrated vector control programs. The initiative focuses on improving early case detection, standardizing treatment protocols, and enhancing reporting systems across high-burden countries such as Ethiopia, Sudan, and South Sudan
• In March 2026, DNDi (Drugs for Neglected Diseases initiative) in collaboration with WHO reported continued advancement in optimized treatment strategies for visceral leishmaniasis, focusing on improved combination regimens such as liposomal amphotericin B with oral miltefosine. The initiative aims to standardize simplified treatment protocols across endemic regions such as South Asia and East Africa to improve cure rates and reduce relapse

SKU-54245